Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

More News! 18 Nov 2017

Bacterial Art Starts a Debate on Money and International Borders

We have been told over and over that bacteria are everywhere around us, especially on your smartphone screen. But most of us haven’t stopped to reflect on the fact — and consequences — of bacteria being all over our money. A scientific study by the New York University called the Dirty Money Project revealed in […]

November 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

hummingbird diagnostics cancer alzheimer parkinson

News and Trends 16 Nov 2017

German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s

Hummingbird Diagnostics has teamed up with Saarland University to develop molecular diagnostics that can detect serious diseases early using blood samples. Based in Heidelberg, Germany, Hummingbird Diagnostics develops early diagnostics in multiple disease areas, ranging from cancer to cardiovascular and neurodegenerative disease. Its technology is based in the detection of miRNA, molecules that are involved […]

November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

moderna biontech personalized cancer vaccine

News and Trends 15 Nov 2017

US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine

Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […]

November 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

imcyse type 1 diabetes immunotherapy cure

News and Trends 15 Nov 2017

Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure

Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen. Originally published on 30/05/2017 Imcyse will run its first clinical trial testing […]

November 15, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2017

This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected

Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body against infections. Unlike it’s done with cancer types that affect other blood cells, it’s […]

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2017

Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low

ProQR is aiming to raise funds for clinical trials on the Nasdaq despite the fact that its stock has been down for a while now. ProQR is a biotech based in Leiden that develops RNA therapies for genetic disorders, with its lead program focused on cystic fibrosis. In order to fund clinical trials, research and […]

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Hubert Birner TVM Capital Bio Europe 2017

Interview 13 Nov 2017

Where is the Money Going in Biotech? A Peek into European VC Strategy

Hubert Birner, Managing Partner at TVM Capital Life Science, discusses his strategy to adapt to the European funding constraints and the areas with most potential for biotech investment. TVM Capital Life Science is a venture capital firm focusing on biotech, pharma and medtech. With over €900M under management and offices in both Munich and Montreal, TVM […]

November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Nov 2017

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […]

November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Nov 2017

Roche Partners with French Startup to Diagnose Septic Shock

In its first partnership with a biotech startup, Roche Diagnostics will help develop a blood test to accompany Inotrem’s experimental therapy for septic shock. Roche Diagnostics has announced a research collaboration with Inotrem, a biotech startup based in Nancy, France. The deal, for which the amount was undisclosed, concerns the development of a companion diagnostic test […]

November 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Evotec CEO Werner Lanthaler Biotech Innovation Partnerships

Interview 9 Nov 2017

Interview with Europe’s Leader in Biotech Partnerships

I talked with Werner Lanthaler, CEO of Evotec, during Bio Europe 2017 to ask him what the key is to his company’s great success in supporting biotech innovation and establishing strategic partnerships. Evotec started off as a contract research organization in Hamburg back in 1993. Today it has over 2,000 employees worldwide, its own pipeline […]

November 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

neurimmune ono pharmaceutical neurodegenerative disease

More News! 9 Nov 2017

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […]

November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández

advicenne distal renal tubular acidosis rare disease

News and Trends 6 Nov 2017

Update: The First Drug for This Rare Kidney Disease May Come From a French Biotech

Update (6/11/2017): ADV7103 has maintained its efficacy in a 6-month extension of the Phase III study. In 79% of the patients, the blood bicarbonate levels were kept within the normal range after 6 months of treatment, further supporting its push to become the first treatment for the disease on the market. Originally published 11/9/2017 Advicenne has […]

November 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us